Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/28306
Title: Miller-Fisher Syndrome and Guillain-Barre Syndrome overlap syndrome in a patient post Oxford-AstraZeneca SARS-CoV-2 vaccination.
Austin Authors: Dang, Yew Li;Bryson, Alexander 
Affiliation: Neurology
Department of Neurology, Box Hill Hospital, Box Hill, Victoria, Australia
Issue Date: 30-Nov-2021
Date: 2021-11-30
Publication information: BMJ Case Reports 2021; 14(11): e246701
Abstract: We describe a patient who developed bilateral oculomotor nerve palsy, ataxia, facial diplegia and lower limb weakness 2 weeks post-Oxford-AstraZeneca SARS-CoV2 vaccination, consistent with Miller-Fisher syndrome (MFS) and Guillain-Barre syndrome (GBS) overlap syndrome. Although some features of the patient's presentation were typical of recently reported cases of a rare GBS variant post-Oxford-AstraZeneca vaccination, including severe facial weakness and a lack of respiratory involvement, to our knowledge this is the first reported case of MFS associated with SARS-CoV2 vaccination. While postvaccination GBS remains rare, it appears to have a favourable prognosis, and recognising this entity is therefore important for patient counselling and monitoring for potential complications.
URI: https://ahro.austin.org.au/austinjspui/handle/1/28306
DOI: 10.1136/bcr-2021-246701
ORCID: 0000-0002-0570-5398
0000-0002-0033-8197
Journal: BMJ Case Reports
PubMed URL: 34848426
Type: Journal Article
Subjects: COVID-19
cranial nerves
neurology
peripheral nerve disease
Appears in Collections:Journal articles

Show full item record

Page view(s)

18
checked on Apr 17, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.